A Comparison of Effect of Dulextine and Nortryptiline in Diabetic Neuropathy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015111113612N7

Enrollment

Registered

2016-05-05

Start date

2016-03-16

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes 2. polyneuropathy

Interventions

In all patients, administration of duloxetine 60 mg daily for 3 months.

Treatment - Drugs

In all patients, administration of duloxetine 60 mg daily for 3 months

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients older than 18 years are at least 3 years have passed since the risk of diabetes, patients with painful diabetic neuropathy, patients who for at least three months before nortriptyline were 25-75 mg. Exclusion criteria: patients with epilepsy, patients with uncontrolled HTN severe, chronic liver disease or kidney disease, patients with other causes of pain are treated.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain and burning. Timepoint: Baseline, one month after discontinuation of the Nortriptyline, after 3 months of initiating Deloxetine. Method of measurement: Based on questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Farzad Najafipour

Tabriz University of Medical Sciences

Najafipourf@gmail.com+98 41333557850

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026